Apogee Therapeutics (APGE) Shares Outstanding (Weighted Average) (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Shares Outstanding (Weighted Average) data on file, last reported at $69.7 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $69.7 million, up 19.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $69.7 million (up 19.71% YoY), and the FY2025 annual result was $60.7 million, up 9.96% from the prior year.
• Shares Outstanding (Weighted Average) advanced to $69.7 million in Q1 2026 per APGE's latest filing, from $60.7 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $69.7 million in Q1 2026 and troughed at $1.2 million in Q2 2022.
• A 5-year average of $37.8 million and a median of $52.3 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Weighted Average) jumped 1883.42% in 2023, then gained 3.39% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $2.5 million in 2022, then jumped by 915.57% to $25.0 million in 2023, then surged by 120.72% to $55.2 million in 2024, then gained by 9.96% to $60.7 million in 2025, then grew by 14.79% to $69.7 million in 2026.
• Business Quant data shows APGE's Shares Outstanding (Weighted Average) at $69.7 million in Q1 2026, $60.7 million in Q4 2025, and $58.8 million in Q3 2025.